Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02298530
Other study ID # REF-BEV-1803
Secondary ID
Status Completed
Phase N/A
First received November 12, 2014
Last updated December 3, 2015
Start date March 2015
Est. completion date November 2015

Study information

Verified date December 2015
Source Unilever R&D
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Assess the effects of adding theanine to a caffeinated beverage on changes in blood pressure during acute mental stress.


Description:

Caffeine and (mental) stress can increase blood pressure. In a typical everyday and/or work environment they commonly coincide. Tea has the reputation of being a relaxing drink. L-theanine is an amino acid found almost exclusively in tea. In a previous study it was shown that caffeine increased blood pressure, while theanine antagonised these effects. In the current study the effect of theanine to a placebo on blood pressure are directly compared.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date November 2015
Est. primary completion date October 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Apparently healthy males and females

- Women taking the contraceptive pill

- 18-45 years of age

- BMI 20-30 kg/m2

- Normal or corrected vision

- Low caffeine consumers (<100mg/day)

- Non smokers and having been a non-smoker for > 6 months

- Fluent English

- Normotensive (>90/60 <140/90 mmHg)

Exclusion Criteria:

- Significant current or medical history of cardiovascular disease

- Low or high STAI trait score in the opinion of the PI

- Known sensitivity to caffeine or theanine

- Colour blindness

- Alcohol consumption above 14/21 units female/male resp. per week

- Weight loss diet > 10% of bodyweight in the previous year

- Anyone with a dependency on PI or staff of Department of Epidemiology and Public Health or being an employee of Unilever

- Reported participation in another biomedical study < 3 months before screening

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Combination of caffeine and theanine
Beverage containing caffeine and theanine
Caffeine
Beverage containing caffeine

Locations

Country Name City State
United Kingdom University College London London

Sponsors (2)

Lead Sponsor Collaborator
Unilever R&D University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Cortisol in saliva before and immediately after stress Concentration of cortisol in saliva -5, 45 min relative to test product intake No
Other Heart rate during stress Heart rate during acute mental stress Between 30-45 minutes after test product intake No
Other Heart rate after stress Heart rate immediately after acute mental stress Between 45-60 minutes after test product intake No
Other Heart rate variability during stress Heart rate variability during acute mental stress Between 30-45 minutes after test product intake No
Other Heart rate variability after stress Heart rate variability immediately after acute mental stress Between 45-60 minutes after test product intake No
Other Performance STROOP Task performance on STROOP task Between 30-45 minutes after test product intake No
Other Performance mirror tracing Task performance on mirror tracing task Between 30-45 minutes after test product intake No
Other Systolic blood pressure, free living phase Ambulatory systolic blood pressure during free living phase Between 80-270 minutes after test product intake No
Other Diastolic blood pressure, free living phase Ambulatory diastolic blood pressure during free living phase Between 80-270 minutes after test product intake No
Other Cortisol, free living phase Concentration of cortisol in saliva during free living phase 140, 200 and 260 minutes after test product intake No
Other STAI, free living phase Self-reported mental state: State-Trait Anxiety Inventory during free living phase 140, 200 and 260 minutes after test product intake No
Other UWIST, free living phase Self-reported mental state: University Of Wales Institute of Science and Technology) mood adjective questionnaire during free living phase 140, 200 and 260 minutes after test product intake No
Other Pulse pressure during stress Mean pulse pressure during mental stress Between 30-45 minutes after test product intake No
Other Pulse pressure after stress Mean pulse pressure after acute mental stress Between 45-60 minutes after test product intake No
Other Mental wellbeing Mental well being as assessed by on line survey an each evening during the 7 day period the accelerometer is worn. 7 consecutive days prior to the lab sessions No
Other Physical activity Habitual patterns in physical activity as measured by accelerometer 7 consecutive days prior to the lab sessions No
Other STAI screening State-Trait Anxiety Inventory (STAI) - Trait version, covariate Screening No
Other CES-D Center for Epidemiologic Studies Depression scale, covariate Screening No
Other CISS CISS coping scale, covariate Screening No
Other loneliness UCLA loneliness scale, covariate Screening No
Other Perceived stress Perceived Stress Scale, covariate Screening No
Primary Systolic blood pressure during stress Systolic blood pressure during acute mental stress Between 30-45 minutes after test product intake No
Secondary Diastolic blood pressure during stress Diastolic blood pressure during acute mental stress Between 30-45 minutes after test product intake No
Secondary Systolic blood pressure after stress Systolic blood pressure immediately after acute mental stress Between 45-60 minutes after test product intake No
Secondary Diastolic blood pressure after stress Diastolic blood pressure immediately after acute mental stress Between 45-60 minutes after test product intake No
Secondary STAI before and immediately after stress Self-reported mental state: State-Trait Anxiety Inventory -15 and 45 relative to test product intake No
Secondary UWIST before and immediately after stress Self-reported mental state: University Of Wales Institute of Science and Technology mood adjective questionnaire -10, 45 minutes relative to test product intake No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1